Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $330
Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and lowers the price target from $360 to $330.
BeiGene: Q4 Earnings Insights
BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
BeiGene Q4 EPS $(6.16) Down From $(5.20) YoY, Sales $214.00M Up From $100.10M YoY
BeiGene (NASDAQ:BGNE) reported quarterly losses of $(6.16) per share. This is a 18.46 percent decrease over losses of $(5.20) per share from the same period last year. The company reported $214.00 million in sales this
BeiGene Announced Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene's BTK inhibitor BRUKINSA (zanubrutinib) received approval from Swissmedic for the treatment of adult patients with Waldenström's macroglobulinemia (WM) who have received at least one prior line of therapy, or for t
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector
By Bamboo Works team
Immix Biopharma’s IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker’s Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
Leap Therapeutics Inc (NASDAQ: LPTX) will present